Special Issue

Antimicrobial Resistance (AMR) in Japan, Present, Past Fact and Next Strategy under COVID-19 Pandemic

Message from the Guest Editor

Antimicrobial resistance (AMR) is one of the most common medical problems in the world and AMR organisms could cause up to 10 million deaths in 2050. In Japan, the AMR action plan has been proposed since 2016 according to WHO recommendation, but the past and current status and the strategy was not recognized enough. For example, methicillin-resistance is still highly frequent (30-50% of *Staphylococcus aureus*), but vancomycin-resistance is rarely isolated (

Guest Editor

Dr. Ken Kikuchi

Department of Infectious Diseases, Tokyo Women's Medical University, Tokyo, Japan

Deadline for manuscript submissions

closed (1 September 2021)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/72948

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

